BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE: KG) reported today that the Company has learned that Actavis, a manufacturer of generic pharmaceutical products headquartered in Iceland, has filed a Paragraph IV Certification with the U.S. Food and Drug Administration (“FDA”) pertaining to King’s product, AVINZA® (morphine sulfate extended release). Allegations of non-infringement in Actavis’s Paragraph IV Certification relate to U.S. Patent No. 6,066,339 (“the ‘339 Patent”). The ‘339 Patent is a utility patent that covers the formulation of AVINZA ®. King, a licensee of the ‘339 Patent, intends to vigorously enforce the patent. The ‘339 Patent extends through November 25, 2017.
